Phase 2 COPD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have received a stem cell transplant from a donor and developed moderate to severe chronic graft-versus-host disease (cGVHD) — a condition where the donor cells attack the recipient's body — that requires treatment with immune-suppressing medicines.
- People who have both an ongoing acute (sudden-onset) form and a chronic form of graft-versus-host disease at the same time (sometimes called overlap syndrome) may also be considered.
- People with active chronic graft-versus-host disease who have already tried and not responded to at least 2 different systemic (whole-body) treatments.
- People who are taking corticosteroids (steroid medicines) at a stable dose for at least 2 weeks before starting the study treatment, or people who are not taking corticosteroids at all.
- People whose heart, liver, kidneys, and bone marrow are functioning at an adequate level.
- People of reproductive potential who agree to follow the contraception requirements set out by the trial.
- People who score 60 or above on the Karnofsky Performance Scale, a measure of a person's ability to carry out daily activities (confirm with trial site).
Who may not be able to join:
- People who have only the acute form of graft-versus-host disease, with no signs of the chronic form.
- People who have previously been treated with a type of medicine called a CSF1R inhibitor for chronic graft-versus-host disease.
- People with a serious uncontrolled illness, uncontrolled infection, or any other health condition that the trial site determines would make participation unsuitable — all wounds must also be fully healed and free of infection.
- People with a history of cancer, except for the original cancer that led to the stem cell transplant, or a previous cancer that was treated with the intention of a cure, shows no signs of returning, and occurred more than 3 years before joining the trial.
- People with a condition that affects the body's ability to absorb medicines taken by mouth, such as malabsorption syndrome.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Team, Deciphera Pharmaceuticals, LLC
Phone: 888-724-3274
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Dose-Limiting Toxicities (DLTs); Number of Participants with Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.